{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:36Z","timestamp":1775695716441,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s40265-017-0724-2","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T07:41:39Z","timestamp":1489390899000},"page":"705-712","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Sarilumab: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"724_CR1","unstructured":"Sanofi-aventis Canada Inc. Kevzara\u2122 (sarilumab): product monograph (Canada). 2017. http:\/\/pdf.hres.ca\/dpd_pm\/00037766.PDF . Accessed 6 Mar 2017."},{"issue":"5","key":"724_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"S Srirangan","year":"2010","unstructured":"Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatois arthritis. Ther Adv Musculoskel Dis. 2010;2(5):247\u201356.","journal-title":"Ther Adv Musculoskel Dis."},{"key":"724_CR3","first-page":"23","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IA. Rheumatoid arthritis. Lancet. 2016;388:23\u201338.","journal-title":"Lancet"},{"key":"724_CR4","unstructured":"Sanofi, Regeneron Pharmaceuticals. Sanofi and Regeneron announce EMA acceptance for review of Marketing Authorisation Application for sarilumab. 2016. http:\/\/www.sanofi.com . Accessed 15 Feb 2017."},{"key":"724_CR5","unstructured":"Sanofi, Regeneron Pharmaceuticals Inc. Sanofi and Regeneron announce first approval of KevzaraTM (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients by Health Canada. 2017. http:\/\/www.sanofi-aventis.com . Accessed 1 Feb 2017."},{"key":"724_CR6","unstructured":"Regeneron Pharmaceuticals. Regeneron report third quarter 2016 financial and operating results. Media release. 2016. http:\/\/newsroom.regeneron.com\/ . Accessed 1 Feb 2017."},{"key":"724_CR7","unstructured":"Sanofi, Regeneron Pharmaceuticals. Juvenile idiopathic arthritis: NCT02776735 and NCT02991469. 2017. http:\/\/clinicaltrials.gov . Accessed 15 Feb 2017."},{"key":"724_CR8","unstructured":"Sanofi, Regeneron Pharmaceuticals. Ankylosing spondylitis: NCT01118728 and NCT01061723. 2017. http:\/\/clinicaltrials.gov\/ . Accessed 15 Feb 2017."},{"key":"724_CR9","unstructured":"Mangan EK, Parrino J, Wu R, et al. Pharmacodynamic effect and safety of single-dose administration of subcutaneous sarilumab or intravenous tocilizumab in patients with rheumatoid arthritis [abstract no. APL16-0768]. Int J Rheum Dis. 2016;19(Suppl 2):196."},{"issue":"1","key":"724_CR10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13075-016-1132-9","volume":"18","author":"A Boyapati","year":"2016","unstructured":"Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18(1):225.","journal-title":"Arthritis Res Ther."},{"key":"724_CR11","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73:1626\u201334.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"724_CR12","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424\u201337.","journal-title":"Arthritis Rheumatol."},{"key":"724_CR13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.","journal-title":"Arthritis Res Ther."},{"issue":"Suppl 2","key":"724_CR14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2016-eular.4363","volume":"75","author":"D Heijde van der","year":"2016","unstructured":"van der Heijde D, Fan C, van Hoogstraten H, et al. Consistency of radiographic responses with sarilumab plus methotrexate across subpopulations of patients with rheumatoid arthritis in a phase 3 study [abstract no. SAT0058]. Ann Rheum Dis. 2016;75(Suppl 2):685.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"724_CR15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/annrheumdis-2016-eular.3133","volume":"75","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Mangan EK, van Adelsberg J, et al. Onset of action of sarilumab in patients with rheumatoid arthritis in 2 phase 3 studies [abstract no. SAT0180]. Ann Rheum Dis. 2016;75(Suppl 2):733.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"724_CR16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1136\/annrheumdis-2016-eular.4214","volume":"75","author":"V Strand","year":"2016","unstructured":"Strand V, Chen C, Mahajan P, et al. Early onset of benefit by patient-reported outcomes (PROs) with sarilumab treatment in RA [abstract no. AB0251]. Ann Rheum Dis. 2016;75(Suppl 2):984\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"724_CR17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active RA and inadequate response or intolerance to tumour necrosis factor inhibitors. Arthritis Rheumatol. 2016;69(2):277\u201390.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 2","key":"724_CR18","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/annrheumdis-2016-eular.4295","volume":"75","author":"V Strand","year":"2016","unstructured":"Strand V, Mahajan P, Chen C, et al. Benefit of sarilumab with csDMARDs on patient productivity in work, household work and family, social, leisure activities in TNF-IR RA patients [abstract no. AB0252]. Ann Rheum Dis. 2016;75(Suppl 2):985.","journal-title":"Ann Rheum Dis"},{"key":"724_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210310","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-210310 .","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"724_CR20","first-page":"515","volume":"75","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Fay J, Parrino J, et al. Sarilumab dose reduction to manage laboratory abnormalities in an open-label extension study in RA patients [abstract no. FRI0228]. Ann Rheum Dis. 2016;75(Suppl 2):515\u20136.","journal-title":"Ann Rheum Dis"},{"key":"724_CR21","unstructured":"Fleischmann R, Genovese MC, van Adelsberg J, et al. Pooled safety and efficacy of sarilumab in rheumatoid arthritis patients 65 years of age and older [abstract no. 1605]. Arthritis Rheumatol. 2016;68(Suppl 10)."},{"key":"724_CR22","unstructured":"Sanofi, Regeneron Pharmaceuticals. Non-infectious uveitis: NCT01900431. 2017. http:\/\/clinicaltrials.gov\/ . Accessed 15 Feb 2017."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0724-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0724-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0724-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:56:58Z","timestamp":1750100218000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0724-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["724"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0724-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}